Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 3
1997 8
1998 18
1999 26
2000 31
2001 19
2002 22
2003 27
2004 21
2005 14
2006 12
2007 9
2008 10
2009 11
2010 12
2011 14
2012 14
2013 7
2014 13
2015 10
2016 5
2017 2
2018 6
2019 8
2020 2
2021 4
2022 2
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Eptifibatide.
[No authors listed] [No authors listed] 2019 Jun 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2019 Jun 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 31260228 Free Books & Documents. Review.
No published information is available on the use of eptifibatide during breastfeeding. Because eptifibatide is a peptide, absorption by the infant is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, …
No published information is available on the use of eptifibatide during breastfeeding. Because eptifibatide is a peptide, abso …
Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice.
Tonin G, Klen J. Tonin G, et al. Int J Mol Sci. 2023 Mar 13;24(6):5446. doi: 10.3390/ijms24065446. Int J Mol Sci. 2023. PMID: 36982519 Free PMC article. Review.
One of the promising peptide drugs in the treatment of these pathologies is eptifibatide, a synthetic heptapeptide derived from rattlesnake venom. Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks different pathways in platelet activation and aggregation …
One of the promising peptide drugs in the treatment of these pathologies is eptifibatide, a synthetic heptapeptide derived from rattl …
Eptifibatide-Induced Thrombocytopenia--When Inhibitor Turns Killer.
Pothineni NV, Watts TE, Ding Z, Dai Y, Deshmukh AJ. Pothineni NV, et al. Am J Ther. 2016 Jan-Feb;23(1):e298-9. doi: 10.1097/01.mjt.0000438283.01797.1a. Am J Ther. 2016. PMID: 24368608 Review.
Eptifibatide is a commonly and widely used drug for management of acute coronary syndrome and during percutaneous coronary intervention. ...We report a rare case of life-threatening thrombocytopenia secondary to eptifibatide along with a literature review of availab …
Eptifibatide is a commonly and widely used drug for management of acute coronary syndrome and during percutaneous coronary interventi …
Targeting integrin pathways: mechanisms and advances in therapy.
Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, Gu Y, Zhao N, Xiang Q, Cui Y. Pang X, et al. Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6. Signal Transduct Target Ther. 2023. PMID: 36588107 Free PMC article. Review.
To date, only seven drugs targeting integrins have been successfully marketed, including abciximab, eptifibatide, tirofiban, natalizumab, vedolizumab, lifitegrast, and carotegrast. ...
To date, only seven drugs targeting integrins have been successfully marketed, including abciximab, eptifibatide, tirofiban, natalizu …
Clinical and economic studies of eptifibatide in coronary stenting.
Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S. Pasala T, et al. Ther Clin Risk Manag. 2014 Aug 2;10:603-14. doi: 10.2147/TCRM.S35664. eCollection 2014. Ther Clin Risk Manag. 2014. PMID: 25120366 Free PMC article. Review.
Although older pharmacoeconomic studies favor eptifibatide, in the current era of P2Y12 inhibitors and newer safer anticoagulants, the increased costs associated with bleeding make the routine use of eptifibatide an economically nonviable option. The cost-effectiven …
Although older pharmacoeconomic studies favor eptifibatide, in the current era of P2Y12 inhibitors and newer safer anticoagulants, th …
Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia.
Vayne C, Guéry EA, Rollin J, Baglo T, Petermann R, Gruel Y. Vayne C, et al. J Clin Med. 2020 Jul 13;9(7):2212. doi: 10.3390/jcm9072212. J Clin Med. 2020. PMID: 32668640 Free PMC article. Review.
Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifibatide, heparin, ibuprofen, mirtazapine, oxaliplatin, penicillin, quinine, quinidine, rifampicin, suramin, tirofiban, trimethoprim-sulfa …
Many drugs can cause immune-mediated thrombocytopenia, but the most commonly implicated are abciximab, carbamazepine, ceftriaxone, eptifi …
Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.
Zhou X, Wu X, Sun H, Li J. Zhou X, et al. J Evid Based Med. 2017 May;10(2):136-144. doi: 10.1111/jebm.12253. J Evid Based Med. 2017. PMID: 28449419 Review.
However, evidences are still lacking on the superiority of eptifibatide over tirofiban or vice versa in patients with acute coronary syndrome. OBJECTIVE: To compare the efficacy and safety of eptifibatide and tirofiban used among patients with acute coronary syndrom …
However, evidences are still lacking on the superiority of eptifibatide over tirofiban or vice versa in patients with acute coronary …
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies.
Liu J, Yang Y, Liu H. Liu J, et al. J Thromb Thrombolysis. 2022 May;53(4):898-910. doi: 10.1007/s11239-021-02584-3. Epub 2021 Nov 15. J Thromb Thrombolysis. 2022. PMID: 34780001 Review.
To review the literature for randomized control trials (RCTs) and prospective cohort studies investigating the safety and efficacy of tirofiban and eptifibatide in patients with acute ischemic stroke (AIS). PubMed, Embase, and the Cochrane library were searched for availab …
To review the literature for randomized control trials (RCTs) and prospective cohort studies investigating the safety and efficacy of tirofi …
How abciximab might be clinically useful.
Usta C, Turgut NT, Bedel A. Usta C, et al. Int J Cardiol. 2016 Nov 1;222:1074-1078. doi: 10.1016/j.ijcard.2016.07.213. Epub 2016 Aug 4. Int J Cardiol. 2016. PMID: 27519521 Review.
In late 1990s, the introduction of GP IIb/IIIa inhibitors (GPI) was associated with a reduction of ischemic complication, and a clear clinical benefit in PCI during ACS, for both non ST-elevation (NSTE) and ST-segment elevation myocardial infarction (STEMI). The currently availab …
In late 1990s, the introduction of GP IIb/IIIa inhibitors (GPI) was associated with a reduction of ischemic complication, and a clear clinic …
50 results